Dr. Hamid on the Efficacy of TILs Following Immunotherapy in Advanced Melanoma

Source: OncLive, January 2022

Omid Hamid, MD, discusses the efficacy of tumor-infiltrating lymphocyte therapy following immunotherapy in advanced melanoma.

Omid Hamid, MD, director, Melanoma Program, Cedars-Sinai Medical Center, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute, discusses the efficacy of tumor-infiltrating lymphocyte (TIL) therapy following immunotherapy in advanced melanoma.

As more data are emerging from large clinical trials, multiple lessons have been learned regarding TIL therapy in melanoma, Hamid says. For example, TIL therapy can be given in any type of hospital setting, meaning it is not limited to academic centers that have facilities where TILs can be manufactured, Hamid explains. Many centers have been able to utilize TILs with the help of newer companies that make the therapies off site, Hamid adds.

READ THE ORIGINAL FULL ARTICLE